XSHE000028
Market cap1.88bUSD
Jan 16, Last price
26.38CNY
1D
-0.83%
1Q
-6.39%
Jan 2017
-48.74%
Name
China National Accord Medicines Corp Ltd
Chart & Performance
Profile
China National Accord Medicines Corporation Ltd. engages in the distribution of medicine and pharmaceutical products. The company sells Chinese traditional, bio-chemical, biological, and diagnosis medicines, as well as antibiotics; chemical preparations; food products; chemical products; and various commodities. It also engages in the sale of medical apparatus and instruments; provision of freight transportation, storage, loading and unloading, and professional consultation services; provision of glass wares, cosmetics, and daily merchandise, as well as goods agency services; import and export of technology; leasing of house properties; and wholesale and retail of health products. As of December 31, 2021, the company operated a network of 8,798 drugstores, including 7,257 directly owned stores and 1,541 franchised stores covering 20 provinces, autonomous regions, and municipalities in China. The company was founded in 2004 and is based in Shenzhen, China. China National Accord Medicines Corporation Ltd. is a subsidiary of Sinopharm Group Co., Ltd.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
---|---|---|---|---|---|---|---|---|---|
2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
Income | |||||||||
Revenues | 75,477,485 2.77% | 73,443,137 7.44% | |||||||
Cost of revenue | 69,303,509 | 69,996,501 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | 6,173,976 | 3,446,636 | |||||||
NOPBT Margin | 8.18% | 4.69% | |||||||
Operating Taxes | 514,739 | 539,332 | |||||||
Tax Rate | 8.34% | 15.65% | |||||||
NOPAT | 5,659,237 | 2,907,303 | |||||||
Net income | 1,599,256 7.57% | 1,486,708 11.24% | |||||||
Dividends | (342,502) | (256,876) | |||||||
Dividend yield | 2.12% | 1.82% | |||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
Debt | |||||||||
Debt current | 12,300,475 | 2,173,505 | |||||||
Long-term debt | 2,903,575 | 2,672,308 | |||||||
Deferred revenue | 80,108 | ||||||||
Other long-term liabilities | 803,243 | 561,964 | |||||||
Net debt | 5,626,376 | (4,092,529) | |||||||
Cash flow | |||||||||
Cash from operating activities | 2,937,139 | 2,560,431 | |||||||
CAPEX | (322,208) | ||||||||
Cash from investing activities | (135,435) | ||||||||
Cash from financing activities | |||||||||
FCF | (6,492,587) | 3,278,151 | |||||||
Balance | |||||||||
Cash | 6,502,348 | 6,016,350 | |||||||
Long term investments | 3,075,327 | 2,921,993 | |||||||
Excess cash | 5,803,801 | 5,266,185 | |||||||
Stockholders' equity | 16,438,985 | 17,326,532 | |||||||
Invested Capital | 29,729,545 | 17,910,070 | |||||||
ROIC | 23.76% | 16.39% | |||||||
ROCE | 17.38% | 14.77% | |||||||
EV | |||||||||
Common stock shares outstanding | 556,565 | 556,565 | |||||||
Price | 28.99 14.58% | 25.30 -11.06% | |||||||
Market cap | 16,134,822 14.58% | 14,081,097 -11.06% | |||||||
EV | 25,324,229 | 13,307,384 | |||||||
EBITDA | 7,599,631 | 4,754,061 | |||||||
EV/EBITDA | 3.33 | 2.80 | |||||||
Interest | 285,043 | 261,908 | |||||||
Interest/NOPBT | 4.62% | 7.60% |